Your search history is turned on.
Date: April 23, 2024 Jurisdictions: Quebec
ARTICLES OF AMENDMENT Relating to STOCK SPLIT TRANSACTION of SUNSHINE BIOPHARMA, INC Pursuant to CRS 7-106-105 of the Colorado Corporations and Associations Act I, Dr. Steve N. Slilaty, President and Chief Executive Officer of Sunshine Biopharma, Inc., (the Company), a corporation organized and existing under the Colorado Corporation and Association Ac...
Material Change Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 SUNSHINE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Colorado 001-41282 2...
Date: April 2, 2024 Jurisdictions: Quebec
CERTIFICATION PURSUANT TO 18 USC, SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002 I, Camille Sebaaly, certify that: 1. I have reviewed this annual report on Form 10-K of Sunshine Biopharma, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in...
CERTIFICATION PURSUANT TO 18 USC, SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002 I, Steve N. Slilaty, certify that: 1. I have reviewed this annual report on Form 10-K of Sunshine Biopharma, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary i...
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ...
EXHIBIT 21.1 SUNSHINE BIOPHARMA, INC. LIST OF SUBSIDIARIES Sunshine Biopharma Canada Inc. Nora Pharma Inc. ...
Exhibit 97.1 SUNSHINE BIOPHARMA, INC. CLAWBACK POLICY EFFECTIVE NOVEMBER 17, 2023 1. Purpose. The purpose of this Sunshine Biopharma, Inc. (the Company) Clawback Policy (this Policy) is to enable the Company to recover Erroneously Awarded Compensation from Covered Executive Officers in the event that the Company is required to prepare an Accounting Restatement. This Polic...
Exhibit 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-264830, 333-263998, and 333-272197) and Form S-8 (No. 333-276417) of our report dated March 28, 2024, relating to the consolidated financial of Sunshine Biopharma, Inc. appearing in this Annual Report on Form 10-K ...